Apatinib as second-line or later therapy in patients with advanced hepatocellular carcinoma (AHELP): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial

Authors: Shukui Qin, Li Qiu, Shanzhi Gu, Xiaoming Chen, Li-zhu Lin, Zishu Wang, Aibing Xu, Xi Chen, Cuncai Zhou, Zhenggang Ren, Lin Yang, Li Xu, Yuxian Bai, Lei Chen, Jun Li, Hongming Pan, Bangwei Cao, Weijia Fang, Wei Wu, Ge Wang, Ying Cheng, Zhuang Yu, Xu Zhu, Da Jiang, Yinying Lu, Huaming Wang, Jianming Xu, Li Bai, Yunpeng Liu, Hailan Lin, Changping Wu, Yang Zhang, Ping Yan, Chunlei Jin, Jianjun Zou - The Lancet 2021 cited by 254